Company Overview and News

 
United States University Announces the Appointment of Dr. Dianna Scherlin as Dean of the College of Nursing

2018-05-07 globenewswire
NEW YORK, May 07, 2018 (GLOBE NEWSWIRE) -- Aspen Group, Inc. (Nasdaq:ASPU), a post-secondary education company, today announced that United States University (USU) has appointed Dr. Dianna Scherlin, DNP, MS, BS, RN as Dean of its burgeoning College of Nursing.

 
ASX:APZ / ASPEN GROUP CURRENT REPORT (Current Report)

2018-04-25 sec.gov
Current Report UNITED STATES

 
ASX:APZ / ASPEN GROUP CURRENT REPORT (Current Report)

2018-04-24 sec.gov
Current Report UNITED STATES

 
Aspen Group, Inc. Announces Early Retirement of $10 million Credit Facility

2018-04-24 globenewswire
NEW YORK, April 24, 2018 (GLOBE NEWSWIRE) -- Aspen Group, Inc. (Nasdaq:ASPU), a post-secondary education company, today announced the early retirement of its $10 million senior secured term loan with Runway Growth Credit Fund, of which $7.5 million was previously drawn down.

 
ASX:APZ / ASPEN GROUP CURRENT REPORT (Current Report)

2018-04-23 sec.gov
Current Report UNITED STATES

 
ASX:APZ / ASPEN GROUP PROSPECTUS SUPPLEMENT (Prospectus)

2018-04-19 sec.gov
Prospectus Supplement Filed pursuant to Rule 424(b)(5) Registration No. 333-224230 PROSPECTUS SUPPLEMENT (To the Prospectus dated April 18, 2018)

 
ASX:APZ / ASPEN GROUP CURRENT REPORT (Current Report)

2018-04-19 sec.gov
Current Report UNITED STATES

 
Aspen Group, Inc. Prices Underwritten Public Offering of Common Stock

2018-04-19 globenewswire
NEW YORK, April 19, 2018 (GLOBE NEWSWIRE) -- Aspen Group, Inc. (Nasdaq:ASPU), a post-secondary education company, today announced the pricing of an underwritten public offering of 2,800,000 shares of its common stock at a price of $7.15 per share. The company has also granted to the underwriters a 30-day option to acquire an additional 420,000 shares to cover overallotments in connection with the offering.

 
ASX:APZ / ASPEN GROUP CURRENT REPORT (Current Report)

2018-04-19 sec.gov
Current Report UNITED STATES

 
ASX:APZ / ASPEN GROUP CURRENT REPORT (Current Report)

2018-04-18 sec.gov
Current Report UNITED STATES

 
ASX:APZ / ASPEN GROUP PROSPECTUS SUPPLEMENT (Prospectus)

2018-04-18 sec.gov
Prospectus Supplement Filed pursuant to Rule 424(b)(5) Registration No. 333-224230 The information in this preliminary prospectus supplement is not complete and may be changed. This preliminary prospectus supplement and the accompany

 
Aspen Group Announces Proposed Public Offering of Common Stock

2018-04-18 globenewswire
NEW YORK, April 18, 2018 (GLOBE NEWSWIRE) -- Aspen Group, Inc. (Nasdaq:ASPU), a post-secondary education company, today announced that it intends to offer shares of its common stock in an underwritten public offering. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

 
ASX:APZ / ASPEN GROUP REGISTRATION STATEMENT

2018-04-11 sec.gov
Registration Statement Registration No. 333-_________ UNITED STATES SECURITIES

 
ASX:APZ / ASPEN GROUP CURRENT REPORT (Current Report)

2018-03-22 sec.gov
Current Report UNITED STATES

Related Articles

ANTH: Anthera Pharmaceuticals Analysis and Research Report

2018-05-21 - Asif

Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...

AGEN: Agenus Inc Analysis and Research Report

2018-05-21 - Asif

Business Agenus is a clinical-stage immuno-oncology (“I-O”) company dedicated to becoming a leader in the discovery and development of innovative combination therapies and committed to bringing effective medicines to patients with cancer. The company's business is designed to drive success in I-O through speed, innovation, and effective combination therapies. Agenus has assembled fully integrated capabilities from novel target discovery, antibody generation, cell line development, and good manufacturing practice (“GMP”) manufacturing together with a comprehensive portfolio consisting of antibody-based therapeutics, adjuvants and cancer vaccine platforms. The company leverage its immune biology platforms to identify effective combination therapies for development and have developed productive partnerships to advance its innovation. The company believe the next generation of cancer treatment will build on clinically validated antibodies targeting CTLA-4 and PD-1 combined wi...

SQ: Square Analysis and Research Report

2018-05-21 - Asif

Business The company started Square in February 2009 to enable businesses (sellers) to accept card payments, an important capability that was previously inaccessible to many businesses. However, sellers also need innovative solutions to thrive, and Square has since expanded to provide additional products and services to give these businesses access to the same tools as large businesses. This approach aligns with its purpose of economic empowerment, as everything the company do should give sellers accessible, affordable tools to grow their businesses and participate in the economy. Square is a cohesive commerce ecosystem that helps its sellers start, run, and grow their businesses. The company combine sophisticated software with affordable hardware to enable sellers to turn mobile and computing devices into powerful payment and point-of-sale solutions. Square has high seller acceptance rates and fast onboarding, while maintaining low risk and fraud losses as a result of its a...